Alvotech (ALVOW)
ALVOWNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)
$0.2753
0.0000 (0.00%) today
Closed, Nov 13, 10:00 AM ET
- Market cap
- $107.49m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1188 to $1.05
- Average volume
- –
- Previous close
- $0.2753
Financials
No quarterly figures from the source.
News
8 latest- Stock Indexes Settle Sharply Lower on Big Tech DrubbingBarchart · 2 minutes ago
- Stem, Inc. Reports Third Quarter 2026 ResultsFintel · 12 minutes ago
- XP Inc. Reports September 30, 2026 Financial Results and Announces New R$ 1.5 billion Share Buy-Back ProgramFintel · 12 minutes ago
- Rapid Micro Biosystems, Inc. to be Acquired by Merck KGaA, Darmstadt, Germany for $0.75 Per ShareFintel · 12 minutes ago
- Cumberland Pharmaceuticals Inc. Announces Phase 2a ASSIST-SSc Trial Top-Line ResultsFintel · 22 minutes ago
- Western Digital Corporation Enters into $1.5 billion Revolving Credit AgreementFintel · 22 minutes ago
- United Maritime Corporation Reports Third Quarter 2026 Net Income of $3.2 Million and Doubles Quarterly Cash Dividend to $0.20 Per ShareFintel · 22 minutes ago
- Mid-America Apartment Communities, Inc. Details $760.0 Million Active Development Pipeline and Financial OutlookFintel · 32 minutes ago
The company
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- alvotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.